ACCESSING CAR-T IN CHINA
THROUGH CANCERFAX
From first contact to leukapheresis in 21โ30 days โ CancerFax reviews eligibility, matches the right hospital, handles logistics, and stays with you through treatment and discharge.
analyticsAt a Glance
- check_circleCancerFax reviews your records and confirms eligibility before recommending any centre or product
- check_circleHospital matching is case-specific โ PUTH, Ruijin, Xuanwu, and SYSUCC each have different disease and protocol strengths
- check_circleFull logistics support: visa invitation letter, interpreter, accommodation guidance, discharge protocol
- check_circleCancerFax cannot guarantee outcomes, trial arm availability, or insurance reimbursement
What CancerFax Does โ and Does Not Do
CancerFax is a specialist cancer navigation platform, not a hospital, clinic, or treatment provider. Our role is to review your case, identify the right pathway, connect you with the right team, and support you through every non-clinical step of the process.
โWe are the bridge between a patient who needs CAR-T and a Chinese oncology team that can deliver it โ and we stay on the bridge throughout.โ
Case Review and Eligibility Assessment
We review your bone marrow biopsy, immunophenotyping, prior treatment lines, organ function results, and performance status. We identify whether you meet the eligibility criteria for approved products or open clinical trials.
Hospital and Physician Matching
We match your case to the appropriate centre based on disease type, target antigen, disease stage, and the specific protocols and trial availability at each hospital. We do not refer all patients to the same hospital.
Logistics and Communication
We provide visa invitation letters, interpreter support throughout the treatment stay, accommodation guidance, discharge protocol translation, and ongoing communication between the treating team and your home physician.
Clinical Treatment or Guarantees
CancerFax does not administer treatment, prescribe, or make clinical decisions. We cannot guarantee remission outcomes, trial arm availability, insurance approval, or that a specific patient will be accepted by a centre.
Which Hospital โ and Why It Matters
China has multiple centres with approved and investigational CAR-T programmes. Each has different disease strengths, protocol availability, and international patient infrastructure. CancerFax selects based on case, not on volume or referral incentives.
Peking University Third Hospital
One of China's highest-volume CAR-T centres with the broadest portfolio of approved products and open trials across B-ALL, DLBCL, and myeloma. Strong international patient infrastructure and published trial outcomes.
Ruijin Hospital (Shanghai Jiao Tong)
A leading haematology centre with strong myeloma CAR-T programmes and bispecific CAR-T constructs. Preferred for BCMA-targeted cases and patients with prior multiple lines of myeloma therapy.
Xuanwu Hospital
Active CAR-T programmes in aggressive B-cell lymphoma and T-cell malignancies. Appropriate for cases involving CNS involvement or unusual B-cell subtypes where more specialised protocols are needed.
Sun Yat-sen University Cancer Centre
Particularly relevant for patients from Southeast Asia and the Middle East due to geographic proximity. Strong nasopharyngeal carcinoma programme and growing CAR-T portfolio for haematological malignancies.
Step-by-Step: First Contact to Leukapheresis
For patients who meet eligibility criteria, the standard timeline from first CancerFax contact to leukapheresis (T-cell collection) is 21โ30 days. Delays occur when documents are incomplete or additional screening is required.
- 1
Day 1 โ First Contact
Patient or family submits records via CancerFax upload portal or WhatsApp. Records should include recent bone marrow biopsy, treatment summary, and latest organ function results.
- 2
Day 3โ5 โ Eligibility Review
CancerFax clinical team reviews records against CAR-T eligibility criteria: antigen confirmation, prior lines, organ function, performance status. A written eligibility assessment is provided with recommended pathway (approved product vs trial).
- 3
Day 7โ14 โ Hospital Confirmation
CancerFax submits the translated case summary to the matched hospital's CAR-T team. The treating physician reviews and provides formal acceptance with a proposed leukapheresis date and cost estimate.
- 4
Day 14โ21 โ Visa and Travel
CancerFax prepares the hospital invitation letter and medical certification for the M visa application. Patient books flights targeting arrival 2โ3 days before leukapheresis. Accommodation is arranged near the hospital.
- 5
Day 21โ30 โ Consultation and Leukapheresis
Inpatient consultation, pre-leukapheresis bloodwork, and confirmatory screening at the hospital. Leukapheresis (T-cell collection) is performed โ a 2โ4 hour apheresis procedure. Manufacturing begins.
- 6
Day 30โ60+ โ Manufacturing Wait
3โ6 week manufacturing period. Patient may remain in China (if bridging therapy needed) or return home (if medically stable and the treating team approves). CancerFax maintains communication with both parties.
- 7
Day 60+ โ Lymphodepletion and Infusion
Patient returns (or remains in China) for 3โ5 days of lymphodepletion chemotherapy followed by CAR-T infusion. Post-infusion monitoring begins with minimum 4 weeks near-hospital stay required.
Process Reference Numbers
- 21โ30 daysContact to LeukapheresisTypical timeline from first CancerFax contact to T-cell collection for eligible patients with complete documentation.
- 48 hoursInitial Eligibility ResponseCancerFax responds to uploaded case records with an initial eligibility assessment within 48 working hours.
- 6โ8 weeksTotal China StayExpected total duration in China from leukapheresis through post-infusion acute monitoring and discharge.
- 4 hospitalsPrimary Partner CentresPUTH (Beijing), Ruijin (Shanghai), Xuanwu (Beijing), and SYSUCC (Guangzhou) โ matched by disease, antigen, and protocol.
More from the CAR-T in China Resource Library
Continue exploring the complete CAR-T treatment guide โ from the main overview to preparation, costs, and clinical topics.
Frequently Asked Questions
Common questions about the CancerFax access process for CAR-T treatment in China.
How does CancerFax decide which hospital to recommend?
Hospital matching is based on four factors: disease type and subtype (e.g., B-ALL vs DLBCL vs myeloma), target antigen confirmed on biopsy, availability of approved product or open trial that matches the patient's prior line profile, and practical factors like centre's international patient capacity and location preference. CancerFax does not receive referral fees from hospitals โ recommendations are clinically driven.
What happens if the hospital rejects my case?
Hospital rejection occurs when the treating physician determines that the patient does not meet fitness criteria, antigen expression is insufficient, or no suitable protocol is currently open. If this happens, CancerFax reviews the case with a second partner centre. If no CAR-T pathway is currently appropriate, we provide an honest assessment and explore alternative options such as bispecific antibody access or other advanced therapy trials.
Do I need to speak Mandarin?
No. CancerFax provides English-Mandarin interpretation throughout the consultation, leukapheresis, infusion, and monitoring period. All key documents (consent forms, treatment protocols, discharge summaries) are translated. For inpatient stays, a dedicated CancerFax point of contact is available for the patient and family via WhatsApp and phone.
How soon do I need to travel after hospital acceptance?
Most hospitals request arrival within 2โ4 weeks of formal acceptance to hold the leukapheresis slot. Delays beyond this window may result in loss of the slot if the treatment calendar fills. CancerFax flags this timeline clearly at the point of acceptance so families can begin visa and travel arrangements immediately.
Can CancerFax help after I return home from China?
Yes. Post-treatment coordination is part of the CancerFax service. This includes preparation of a bilingual discharge protocol for the home-country physician, IVIG schedule and monitoring plan, viral PCR follow-up schedule, and an introduction between the Chinese treating team and the home physician for ongoing queries. We remain available for clinical communication questions during the post-infusion monitoring period.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Send Your Records โ We'll Review Within 48 Hours
Upload your recent bone marrow biopsy, prior treatment summary, and organ function results. CancerFax's clinical team reviews your case and responds with a structured eligibility assessment and recommended pathway.
CancerFax is a patient navigation service and does not provide medical treatment. All clinical decisions are made by the treating physicians at the partner hospital.